Biogen has unveiled new Tecfidera research that, it says, reinforces its efficacy in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients and further supports its long-term, well-characterised safety profile. The data was presented at the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada.
Data from a post-hoc analysis show that more than half of newly diagnosed patients treated with Tecfidera were free from relapses and disability progression for six years, reinforcing that early, effective treatment with Tecfidera improves long-term clinical outcomes. Additional real-world data from a claims database indicate that Tecfidera is associated with significantly lower annualised relapse rates (ARR).
“The MS treatment landscape has expanded rapidly in recent years, giving physicians and patients options for various stages of disease. Beyond clinical findings, real-world data provides important insights into patients’ experiences outside of clinical trials,” said Kate Dawson, M.D., vice president, U.S. Medical.
“This data shows Tecfidera consistently delivers strong and sustained efficacy in newly diagnosed patients both in a real-world and clinical setting, further supporting the value it offers patients and affirming the advantages of early treatment with Tecfidera in decreasing clinical disease activity.”
Source: Streetinsider.com © Copyright 2016 StreetInsider.com (19/04/16)